Vertex Pharmaceuticals (1VRTX) AI Stock Analysis

Company Guidance

Vertex raised full‑year 2026 revenue guidance to $13.1–$13.2 billion while reiterating expectations for at least $500 million of non‑CF revenue and a roughly 150 basis‑point net benefit from foreign exchange; full‑year gross margin is expected to be just under 86% and combined non‑GAAP operating expenses are guided to $5.65–$5.75 billion (with management expecting to be at the high end). They expect a non‑GAAP effective tax rate of 19.5%–20.5% for 2026 (YTD at 20.4%), noted that the pending Crinetics acquisition (~$8.8 billion net of cash, to be funded with cash plus a $4.5 billion term loan) is expected to close in Q3 with modest 2026 P&L impact and to be accretive to non‑GAAP operating income in 2029, and said they will update 2026 guidance at close. Quarterly metrics highlighted alongside guidance included Q2 revenue of $3.3 billion (+12% YoY, with ~170 bps FX benefit), Q2 gross margin of 85.6%, Q2 non‑GAAP EPS of $4.73 (+5% YoY), Q2 non‑GAAP R&D of $889 million and SG&A of $520 million, cash and investments of ~$13.6 billion, and Q2 share repurchases of ~$455 million (~1 million shares).